کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1392793 | 1501161 | 2012 | 14 صفحه PDF | دانلود رایگان |
We recently reported a series of 1,6-disubstituted indoline-based thiophene amidine compounds (5) as selective neuronal nitric oxide synthase (nNOS) inhibitors to mitigate the cardiovascular liabilities associated with hERG K+ channel inhibition (IC50 = 4.7 μM) with previously reported tetrahydroquinoline-based selective nNOS inhibitors (4). The extended structure–activity relationship studies within the indoline core led to the identification of 43 as a selection candidate for further evaluations. The in vivo activity in two different pain (spinal nerve ligation and migraine pain) models, the excellent physicochemical and pharmacokinetic properties, oral bioavailability (Fpo = 91%), and the in vitro safety profile disclosed in this report make 43 an ideal candidate for further evaluation in clinical applications related to migraine pain.
Figure optionsDownload as PowerPoint slideHighlights
► A novel class of sixteen 1,5-disubstituted indoline derivatives were synthesized.
► These compounds were shown to be potent and selective inhibitors of human nNOS.
► These compounds mitigate cardiovascular liabilities (eNOS and hERG K+ activity).
► Therapeutic application was shown in two different pain (SNL and Migraine) models.
► Therapeutic application was further supported by safe side activity profile of 43.
Journal: European Journal of Medicinal Chemistry - Volume 55, September 2012, Pages 94–107